David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective

2017 ASCO Annual Meeting
Tweet this page

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.

Advertisement

Advertisement



Advertisement